Health Sciences Acquisitions Co. 2 (HSAQ) Competitors $5.28 -0.16 (-2.94%) As of 01/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends HSAQ vs. ANIK, CATX, RCEL, ARAY, PROF, SKIN, UTMD, OBIO, BWAY, and KRMDShould you be buying Health Sciences Acquisitions Co. 2 stock or one of its competitors? The main competitors of Health Sciences Acquisitions Co. 2 include Anika Therapeutics (ANIK), Perspective Therapeutics (CATX), AVITA Medical (RCEL), Accuray (ARAY), Profound Medical (PROF), Beauty Health (SKIN), Utah Medical Products (UTMD), Orchestra BioMed (OBIO), BrainsWay (BWAY), and KORU Medical Systems (KRMD). These companies are all part of the "surgical & medical instruments" industry. Health Sciences Acquisitions Co. 2 vs. Anika Therapeutics Perspective Therapeutics AVITA Medical Accuray Profound Medical Beauty Health Utah Medical Products Orchestra BioMed BrainsWay KORU Medical Systems Anika Therapeutics (NASDAQ:ANIK) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Does the media favor ANIK or HSAQ? In the previous week, Health Sciences Acquisitions Co. 2 had 2 more articles in the media than Anika Therapeutics. MarketBeat recorded 2 mentions for Health Sciences Acquisitions Co. 2 and 0 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score. Company Overall Sentiment Anika Therapeutics Neutral Health Sciences Acquisitions Co. 2 Neutral Which has stronger valuation & earnings, ANIK or HSAQ? Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Anika Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnika Therapeutics$166.66M1.45-$82.67M-$6.65-2.48Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A Is ANIK or HSAQ more profitable? Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Anika Therapeutics' net margin of -59.40%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Anika Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Anika Therapeutics-59.40% -2.22% -1.75% Health Sciences Acquisitions Co. 2 N/A N/A -2.38% Do analysts prefer ANIK or HSAQ? Anika Therapeutics presently has a consensus target price of $24.50, suggesting a potential upside of 48.48%. Given Anika Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Anika Therapeutics is more favorable than Health Sciences Acquisitions Co. 2.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anika Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, ANIK or HSAQ? Anika Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Does the MarketBeat Community prefer ANIK or HSAQ? Anika Therapeutics received 303 more outperform votes than Health Sciences Acquisitions Co. 2 when rated by MarketBeat users. CompanyUnderperformOutperformAnika TherapeuticsOutperform Votes30364.33% Underperform Votes16835.67% Health Sciences Acquisitions Co. 2N/AN/A Do insiders & institutionals have more ownership in ANIK or HSAQ? 91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 7.9% of Anika Therapeutics shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryAnika Therapeutics beats Health Sciences Acquisitions Co. 2 on 8 of the 13 factors compared between the two stocks. Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HSAQ vs. The Competition Export to ExcelMetricHealth Sciences Acquisitions Co. 2Surgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.20M$4.81B$5.38B$9.10BDividend YieldN/A52.58%5.37%3.99%P/E RatioN/A14.7661.9313.82Price / SalesN/A58.881,263.6782.69Price / CashN/A50.8943.7436.83Price / Book-8.527.904.964.69Net Income-$380,000.00$13.87M$117.89M$224.57M7 Day Performance0.19%2.34%1.74%1.69%1 Month Performance7.32%11.37%3.68%5.34%1 Year Performance-39.45%32.02%26.10%21.47% Health Sciences Acquisitions Co. 2 Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HSAQHealth Sciences Acquisitions Co. 2N/A$5.28-2.9%N/A-39.4%$59.20MN/A0.004News CoverageANIKAnika Therapeutics3.5809 of 5 stars$16.07-0.7%$24.50+52.5%-25.8%$235.43M$166.66M-2.42300CATXPerspective Therapeutics3.0586 of 5 stars$3.43+8.5%$15.14+341.5%N/A$231.83M$1.43M0.0070Analyst RevisionRCELAVITA Medical2.0222 of 5 stars$8.65+1.3%$18.00+108.1%-37.2%$226.80M$50.14M-3.88130Analyst RevisionARAYAccuray4.5814 of 5 stars$2.24-2.6%$9.00+301.8%-19.4%$225.28M$446.55M-13.181,040Upcoming EarningsNews CoveragePROFProfound Medical2.5483 of 5 stars$7.35-1.1%$14.25+93.9%-8.7%$220.72M$7.20M-5.49150SKINBeauty Health1.7182 of 5 stars$1.74+7.4%$2.55+46.6%-25.5%$215.97M$398M-4.141,030UTMDUtah Medical Products3.0202 of 5 stars$62.16+0.3%N/A-23.3%$210.72M$50.22M14.56180Upcoming EarningsPositive NewsOBIOOrchestra BioMed1.9825 of 5 stars$5.28-2.9%$16.25+207.8%-40.7%$200.69M$2.76M-3.284Positive NewsGap DownBWAYBrainsWay2.5499 of 5 stars$10.23-0.9%$13.17+28.7%+73.5%$192.43M$31.78M102.31120Positive NewsGap UpKRMDKORU Medical Systems1.6667 of 5 stars$4.09+2.3%$4.50+10.0%+100.0%$187.49M$28.52M-16.3680Gap UpHigh Trading Volume Related Companies and Tools Related Companies Anika Therapeutics Competitors Perspective Therapeutics Competitors AVITA Medical Competitors Accuray Competitors Profound Medical Competitors Beauty Health Competitors Utah Medical Products Competitors Orchestra BioMed Competitors BrainsWay Competitors KORU Medical Systems Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HSAQ) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Health Sciences Acquisitions Co. 2 Please log in to your account or sign up in order to add this asset to your watchlist. Share Health Sciences Acquisitions Co. 2 With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
